SCHEMBL4675641

SCHEMBL4675641

O=C(Cc1ccc(Cc2ccccc2F)s1)C(=O)c1nn[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ABL1 P00519 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
MAP4K1 Q92918 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
GLS O94925 2/20 0.34
CES1 P23141 1/20 0.34
NCEH1 Q6PIU2 1/20 0.34
ACHE P22303 1/20 0.34
AR P10275 1/20 0.33
ALDH1A1 P00352 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ERCC5 P28715 1/20 0.33
FEN1 P39748 1/20 0.33
HPGD P15428 1/20 0.33
CXCR3 P49682 1/20 0.32
TP53 P04637 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4680407 0.83 CES1 (0.44) CES1NCEH1ALDH1A1L3MBTL1ERCC5
SCHEMBL4673451 0.83 PTPN1 (0.35) NPC1RAB9AABL1PTGDR2MEN1
SCHEMBL4680232 0.83 PTGDR2 (0.35) NPC1RAB9AABL1PTGDR2MEN1
SCHEMBL4670936 0.82 ABL1 (0.38) NPC1RAB9AABL1MAP4K1MEN1
SCHEMBL4676361 0.82 PTGDR2 (0.35) NPC1RAB9APTGDR2MEN1KMT2A
SCHEMBL4674402 0.82 PTGDR2 (0.35) NPC1RAB9APTGDR2CES1NCEH1
SCHEMBL4670733 0.82 AR (0.36) NPC1RAB9APTGDR2MEN1KMT2A
SCHEMBL4675642 0.81 ALOX5 (0.36) NPC1RAB9AABL1PTGDR2MEN1
SCHEMBL4677164 0.81 PTGDR2 (0.38) NPC1RAB9APTGDR2MEN1KMT2A
SCHEMBL4671973 0.81 ERCC5 (0.36) NPC1RAB9APTGDR2CES1NCEH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NPC1 934/4885RAB9A 2021/4885ABL1 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.